24 April 2026
EMA recommends Redemplo for adults with familial chylomicronaemia syndrome (FCS)
siRNA blocking APOC3 cut triglycerides 80% vs 17% in trial; lowered acute pancreatitis rates; given subcutaneously every 3 months; common AEs: hyperglycaemia, headache, nausea.
